3 Reasons Caribou Biosciences Could Be the Best Gene-Editing Stock for Your Portfolio
- Oops!Something went wrong.Please try again later.
- Oops!Something went wrong.Please try again later.
Caribou Biosciences (NASDAQ: CRBU) filed its paperwork for an initial public offering (IPO) only days after Intellia's announcement. The company was co-founded by Jennifer Doudna, who shared the 2020 Nobel Prize in Chemistry for her discovery of the CRISPR-Cas9 gene-editing tool. Although she is not employed by the company, she still serves on its scientific advisory board.